June 4, 2021

John Theurer Cancer Center investigators report new findings at American Society of Clinical Oncology 2021 Annual Meeting

Researchers from Hackensack University Medical Centers John Theurer Cancer Center, a part of Georgetown Lombardi Comprehensive Cancer Center, are presenting data from 25 studies at the Annual Meeting of the American Society of Clinical Oncology, the largest gathering of cancer professionals in the country. This years meeting is being held virtually June 4-8, 2021. Abstracts of the studies can be viewed at abstracts.asco.org.

At John Theurer Cancer Center patients have access to the latest cancer treatments and technologies, including those being evaluated in clinical trials. People with all types and stages of cancer are treated by world-renown experts. The cancer center is especially well-known for its research that drives treatment guidelines, and expertise in the management of hematologic cancers, having pioneered more effective therapies for leukemia, lymphoma, and multiple myeloma. John Theurer Cancer Center was the first center in New Jersey to offer CAR T-cell therapy, a revolutionary immunotherapy for patients with select leukemias and lymphomas. The center is home to one of the nations largest bone marrow transplant programs, with more than 7,500 completed.

Many of the studies being presented at ASCO report on novel treatments for patients with recurrent or persistent multiple myeloma or non-Hodgkin lymphomas (including mantle cell lymphoma, an especially challenging type), as well as acute myeloid leukemia and chronic lymphocytic leukemia. John Theurer Cancer Center investigators are also leaders in the development of immunotherapy regimens, and several of the studies being presented at ASCO evaluated its effectiveness and side effects, including real-world data in unique patient populations. Other studies report provocative findings on targeted therapies and other treatments for kidney and bladder cancers, brain cancer, and other solid tumors. Data from the following studies by John Theurer Cancer Center researchers are being presented at ASCOs 2021 virtual meeting:

Blood Cancers and Stem Cell Transplantation

Developmental Therapeutics and Immunotherapy

Targeted Therapies and Tumor Biology

Central Nervous System Tumors

The COVID-19 pandemic challenged health care in ways we have never been challenged before. Despite the obstacles it presented, however, investigators at John Theurer Cancer Center continued to expand our understanding of cancer, refine its treatment, and develop innovative approaches to improve patient outcomes," asserted Andre Goy, M.D., M.S., chairman and executive director of John Theurer Cancer Center.

Read more here:
Innovative research refines the treatment of patients with advanced cancers and the use of immunotherapy - Network News, Press Releases - Hackensack...